Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Protein Inhibits Breast Cancer Spread

By Biotechdaily staff writers
Posted on 17 Feb 2005
The existence of a protein called Stat5 has been shown to prevent laboratory-cultured breast cancer cells from becoming aggressive and invasive, according to a new study. More...


"This new insight is significant because it is the invasive behavior of breast cancer cells that leads to the formation of metastatic cancer, the most advanced and serious form of the disease,” stated Hallgeir Rui, M.D., Ph.D., associate professor of oncology, Lombardi Comprehensive Cancer Center at Georgetown University (Washington, DC, USA), and lead researcher of the study.

The study, published in the January 27, 2005, issue of the journal Oncogene, demonstrated that when Stat5 was active, breast cancer cells were not only less invasive, but also gathered into clusters, resembling healthy breast cells. Conversely, the loss of Stat5 triggered invasive tumor cell activities. This new study could possibly lead to better treatments for breast cancer patients.

"The apparent suppressive role of Stat5 in breast cancer is surprising in light of the tumor-promoting role that Stat5 appears to play in leukemias, lymphomas, and prostate cancer,” observed Dr. Rui. "On the other hand, the new data may not be so unexpected since Stat5 is known to promote differentiation of healthy breast cells. Differentiation is a form of orderliness that is gradually lost as cancer cells become more aggressive and invasive.”

Stat5 binds to DNA and controls the expression of specific genes, many of which are still unknown. During pregnancy, this protein is triggered by the hormone prolactin, and triggers the production of milk in the breast. In similar studies, Dr. Rui and coworkers have demonstrated that Stat5 stays active in healthy breast cells in women who are not pregnant. Active Stat5, however, is lost in many breast cancers, particularly as the tumors become more metastatic and aggressive.

Dr. Rui warns that this study was done with cancer cells grown in the lab and that additional research is needed to determine whether this protein also inhibits invasion of human breast cells in mice. This research is ongoing and the outcome will determine whether new treatments could be created to take advantage of the invasion-suppressive role of Stat5 in breast cancer cells. Because Stat5 is a protein that is situated inside the cell, it cannot be injected to slow down breast cancer cell growth. Dr. Rui's lab, however, is assessing newer ways of turning Stat5 back on in breast cancer cells.

The present study supports earlier findings by Dr. Rui and coworkers that in patients whose tumors had not yet metastasized to the lymph nodes, loss of Stat5 was linked with an almost 7.5-fold increased risk of death from recurring cancer. This research now provides a mechanism to explain why this protein maybe a valuable tumor marker to predict risk and outcome in early-stage breast cancer patients.




Related Links:
Georgetown University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.